Straits Times Index
3,294.91 +22.19 (+0.68%) Nikkei
38,356.45 +804.29 (+2.14%) Hang Seng
17,110.21 +281.28 (+1.67%) FTSE 100
8,044.81 +20.94 (+0.26%) Bitcoin USD
66,733.67 +259.35 (+0.39%) CMC Crypto 200
1,437.55 +22.79 (+1.61%)
Alimera Sciences, Inc. (ALIM)
| Previous close | 3.5400 |
| Open | 3.5732 |
| Bid | 3.5200 x 100 |
| Ask | 3.6500 x 100 |
| Day's range | 3.5199 - 3.6300 |
| 52-week range | 1.5600 - 4.3800 |
| Volume | |
| Avg. volume | 73,025 |
| Market cap | 187.953M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of (i) Mr. Todd Wood as President of U.S. Operations of the Company, (ii) Mr. Elliot Maltz as Chief Financial
- GlobeNewswire
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the first patient has been randomized in the DRCR Retina Network’
- GlobeNewswire
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the fourth quarter and full year 2023. Alimera will host a confer
